Susan M. Molineaux Ph.D.
Net Worth

Last updated:

What is Susan M. Molineaux Ph.D. net worth?

The estimated net worth of Dr. Susan M. Molineaux Ph.D. is at least $8,086,216 as of 10 Nov 2021. He owns shares worth $16,716 as insider and has received compensation worth at least $8,069,500 in Calithera Biosciences, Inc..

What is the salary of Susan M. Molineaux Ph.D.?

Dr. Susan M. Molineaux Ph.D. salary is $806,950 per year as Founder, Chief Executive Officer, Pres & Director in Calithera Biosciences, Inc..

How old is Susan M. Molineaux Ph.D.?

Dr. Susan M. Molineaux Ph.D. is 71 years old, born in 1954.

What stocks does Susan M. Molineaux Ph.D. currently own?

As insider, Dr. Susan M. Molineaux Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Calithera Biosciences, Inc. (CALA) Founder, Chief Executive Officer, Pres & Director 557,188 $0.03 $16,716

What does Calithera Biosciences, Inc. do?

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

CALA logo
CALA
Calithera Biosciences, Inc.
$0.03

Susan M. Molineaux Ph.D. insider trading

Calithera Biosciences, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 100,000 $0.85 $84,700
Purchase
Common Stock 51,600 $3.88 $200,208
Option
Employee Stock Option (Right to Buy) 33,790 $1.32 $44,603
Option
Common Stock 26,992 $2.64 $71,259
Option
Common Stock 12,868 $1.8 $23,162
Option
Common Stock 12,868 $1.8 $23,162
Option
Employee Stock Option (Right to Buy) 15,568 $1.2 $18,682
Option
Common Stock 21,933 $1.8 $39,479
Option
Common Stock 21,933 $1.8 $39,479
Option
Employee Stock Option (Right to Buy) 32,100 $0.9 $28,890
Option
Common Stock 29,385 $1.36 $39,964
Option
Employee Stock Option (Right to Buy) 41,720 $0.82 $34,044
Option
Common Stock 29,385 $1.36 $39,964
Option
Employee Stock Option (Right to Buy) 37,992 $0.76 $28,874
Option
Common Stock 27,825 $1.14 $31,720
Option
Common Stock 76,287 $1.14 $86,967
Option
Stock Option (Right to Buy) 100,662 $0.76 $76,503

Calithera Biosciences key executives

Calithera Biosciences, Inc. executives and other stock owners filed with the SEC: